FDA oncology roundup: drugs, imaging agents and diagnostics gain approval

The FDA has cleared several oncology products over the past few days, ranging from therapies to diagnostic and imaging tools. The FDA has cleared several oncology products over the past few days, ranging from therapies to diagnostic and imaging tools. Between the 12-15 June 2026, the FDA approved multiple oncology products, including a new prostate cancer medicine, a CDx and an imaging contrast agent. Credit: Nichcha / Shutterstock.com. Over the last few days, the US Food and Drug Administration (FDA) has granted approval to several oncology products across both the pharmacological, imaging and companion diagnostic (CDx) realms – offering patients…

Source: Medical Device Network